SCM
KYMR icon

Soleus Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Soleus Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,116
Closed -$1.09M – 70
2021
Q1 		$1.09M Buy
28,116
+15,000
+114% +$903K 0.2% 65
2020
Q4 		$813K Sell
13,116
-2,189
-14% -$107K 0.11% 57
2020
Q3 		$495K Buy
+15,305
New +$467K 0.26% 56

Other funds holding KYMR

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DIC
Deer IX & Co Larchmont, New York $971M AUM 24.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Soleus Capital Management's KYMR Position: Q2 2021 in Review

Soleus Capital Management sold out of Kymera Therapeutics (KYMR) in Q2 2021, closing a stake of 28,116 shares — an estimated $1.09M sold.

Soleus Capital Management first reported a position in KYMR in Q3 2020 and held it in 3 quarters. The position peaked at $1.09M in Q1 2021. 110 funds tracked by Wall St. Rank hold KYMR as of Q2 2021.

  • Soleus Capital Management reported no remaining Kymera Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Soleus Capital Management sold 28,116 Kymera Therapeutics shares in Q2 2021, an estimated $1.09M.
  • Soleus Capital Management first reported a position in Kymera Therapeutics in Q3 2020 and held it in 3 quarters.
  • Soleus Capital Management's Kymera Therapeutics position peaked at $1.09M in Q1 2021.
  • 110 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2021.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.